Contact this trialFirst, we need to learn more about you.
Alkylating agents
N-803 + Standard Care for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Sioux Falls, South Dakota
This trial is testing a new cancer drug, N-803, to see if it is safe and effective when used with the current standard of care for advanced or metastatic non-small cell lung cancer (NSCLC). Patients will be randomly assigned to receive either N-803 + standard of care or standard of care alone. The trial will last up to 2 years, and patients will be monitored for disease progression, post-therapies, and survival.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.